131 related articles for article (PubMed ID: 36303228)
1. Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study.
Spalato-Ceruso M; Bouteiller F; Guegan JP; Toulmonde M; Bessede A; Kind M; Cousin S; Buy X; Palussiere J; Le Loarer F; Dadone-Montaudie B; Pulido M; Italiano A
J Hematol Oncol; 2022 Oct; 15(1):157. PubMed ID: 36303228
[TBL] [Abstract][Full Text] [Related]
2. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
Toulmonde M; Penel N; Adam J; Chevreau C; Blay JY; Le Cesne A; Bompas E; Piperno-Neumann S; Cousin S; Grellety T; Ryckewaert T; Bessede A; Ghiringhelli F; Pulido M; Italiano A
JAMA Oncol; 2018 Jan; 4(1):93-97. PubMed ID: 28662235
[TBL] [Abstract][Full Text] [Related]
3. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide.
Toulmonde M; Guegan JP; Spalato-Ceruso M; Peyraud F; Kind M; Vanhersecke L; Le Loarer F; Perret R; Cantarel C; Bellera C; Bessede A; Italiano A
Mol Cancer; 2024 Feb; 23(1):38. PubMed ID: 38378555
[TBL] [Abstract][Full Text] [Related]
4. Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study.
Sun CM; Toulmonde M; Spalato-Ceruso M; Peyraud F; Bessede A; Kind M; Cousin S; Buy X; Palussiere J; Bougouin A; Sautès-Fridman C; Fridman HW; Pulido M; Italiano A
Mol Cancer; 2024 Feb; 23(1):37. PubMed ID: 38374062
[TBL] [Abstract][Full Text] [Related]
5. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.
Halwani AS; Panizo C; Isufi I; Herrera AF; Okada CY; Cull EH; Kis B; Chaves JM; Bartlett NL; Ai W; de la Cruz-Merino L; Bryan LJ; Houot R; Linton K; Briones J; Chau I; von Keudell GR; Lu H; Yakovich A; Chen M; Meulen Jh T; Yurasov S; Hsu FJ; Flowers CR
Leuk Lymphoma; 2022 Apr; 63(4):821-833. PubMed ID: 34865586
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.
Italiano A; Bessede A; Pulido M; Bompas E; Piperno-Neumann S; Chevreau C; Penel N; Bertucci F; Toulmonde M; Bellera C; Guegan JP; Rey C; Sautès-Fridman C; Bougoüin A; Cantarel C; Kind M; Spalato M; Dadone-Montaudie B; Le Loarer F; Blay JY; Fridman WH
Nat Med; 2022 Jun; 28(6):1199-1206. PubMed ID: 35618839
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma.
Bhatia S; Miller NJ; Lu H; Longino NV; Ibrani D; Shinohara MM; Byrd DR; Parvathaneni U; Kulikauskas R; Ter Meulen J; Hsu FJ; Koelle DM; Nghiem P
Clin Cancer Res; 2019 Feb; 25(4):1185-1195. PubMed ID: 30093453
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study.
Le Cesne A; Marec-Berard P; Blay JY; Gaspar N; Bertucci F; Penel N; Bompas E; Cousin S; Toulmonde M; Bessede A; Fridman WH; Sautes-Fridman C; Kind M; Le Loarer F; Pulido M; Italiano A
Eur J Cancer; 2019 Sep; 119():151-157. PubMed ID: 31442817
[TBL] [Abstract][Full Text] [Related]
9. Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial.
Seo YD; Lu H; Black G; Smythe K; Yu Y; Hsu C; Ng J; Hermida de Viveiros P; Warren EH; Schroeder BA; O'Malley RB; Cranmer LD; Loggers ET; Wagner MJ; Bonham L; Pillarisetty VG; Kane G; Berglund P; Hsu FJ; Mi X; Alexiev BA; Pierce RH; Riddell SR; Jones RL; Ter Meulen J; Kim EY; Pollack SM
JAMA Oncol; 2023 Dec; 9(12):1660-1668. PubMed ID: 37824131
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma.
Toulmonde M; Cousin S; Kind M; Guegan JP; Bessede A; Le Loarer F; Perret R; Cantarel C; Bellera C; Italiano A
J Hematol Oncol; 2022 Oct; 15(1):149. PubMed ID: 36271420
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome Analysis of Tumor-Infiltrating Lymphocytes Identifies NK Cell Gene Signatures Associated With Lymphocyte Infiltration and Survival in Soft Tissue Sarcomas.
Judge SJ; Bloomstein JD; Sholevar CJ; Darrow MA; Stoffel KM; Vick LV; Dunai C; Cruz SM; Razmara AM; Monjazeb AM; Rebhun RB; Murphy WJ; Canter RJ
Front Immunol; 2022; 13():893177. PubMed ID: 35874727
[TBL] [Abstract][Full Text] [Related]
13. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.
Wilky BA; Trucco MM; Subhawong TK; Florou V; Park W; Kwon D; Wieder ED; Kolonias D; Rosenberg AE; Kerr DA; Sfakianaki E; Foley M; Merchan JR; Komanduri KV; Trent JC
Lancet Oncol; 2019 Jun; 20(6):837-848. PubMed ID: 31078463
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of the post-treatment T cell composition and spatial organization in soft tissue sarcoma patients treated with neoadjuvant hyperthermic radio(chemo)therapy.
Rupp L; Resag A; Potkrajcic V; Warm V; Wehner R; Jöhrens K; Bösmüller H; Eckert F; Schmitz M
Front Immunol; 2023; 14():1185197. PubMed ID: 37261361
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
16. B cells are associated with survival and immunotherapy response in sarcoma.
Petitprez F; de Reyniès A; Keung EZ; Chen TW; Sun CM; Calderaro J; Jeng YM; Hsiao LP; Lacroix L; Bougoüin A; Moreira M; Lacroix G; Natario I; Adam J; Lucchesi C; Laizet YH; Toulmonde M; Burgess MA; Bolejack V; Reinke D; Wani KM; Wang WL; Lazar AJ; Roland CL; Wargo JA; Italiano A; Sautès-Fridman C; Tawbi HA; Fridman WH
Nature; 2020 Jan; 577(7791):556-560. PubMed ID: 31942077
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
Chugh R; Griffith KA; Davis EJ; Thomas DG; Zavala JD; Metko G; Brockstein B; Undevia SD; Stadler WM; Schuetze SM
Ann Oncol; 2015 Jul; 26(7):1459-64. PubMed ID: 25858498
[TBL] [Abstract][Full Text] [Related]
18. Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Baldini C; Danlos FX; Varga A; Texier M; Halse H; Mouraud S; Cassard L; Champiat S; Signolle N; Vuagnat P; Martin-Romano P; Michot JM; Bahleda R; Gazzah A; Boselli L; Bredel D; Grivel J; Mohamed-Djalim C; Escriou G; Grynszpan L; Bigorgne A; Rafie S; Abbassi A; Ribrag V; Postel-Vinay S; Hollebecque A; Susini S; Farhane S; Lacroix L; Parpaleix A; Laghouati S; Zitvogel L; Adam J; Chaput N; Soria JC; Massard C; Marabelle A
J Exp Clin Cancer Res; 2022 Jul; 41(1):217. PubMed ID: 35794623
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer.
Yarchoan M; Huang CY; Zhu Q; Ferguson AK; Durham JN; Anders RA; Thompson ED; Rozich NS; Thomas DL; Nauroth JM; Rodriguez C; Osipov A; De Jesus-Acosta A; Le DT; Murphy AG; Laheru D; Donehower RC; Jaffee EM; Zheng L; Azad NS
Cancer Med; 2020 Feb; 9(4):1485-1494. PubMed ID: 31876399
[TBL] [Abstract][Full Text] [Related]
20. IDO Targeting in Sarcoma: Biological and Clinical Implications.
Nafia I; Toulmonde M; Bortolotto D; Chaibi A; Bodet D; Rey C; Velasco V; Larmonier CB; Cerf L; Adam J; Le Loarer F; Savina A; Bessede A; Italiano A
Front Immunol; 2020; 11():274. PubMed ID: 32194552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
